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months from index date were identified. ADs were categorized as tricyclic antide-
pressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and new antide-
pressants (NADs). The adherence measures of AD therapy include 90-days medi-
cation possession ratio (MPR, 75% as nonadherent), persistence (duration of
uninterrupted therapy 90 dayswith 14-day permissible gap), and switching of AD
class within 180-days were used. Relapse was defined as hospitalization or emer-
gency department visit due to depression, suicide attempts, or reinitiation of AD
therapy after at least 6 months from previous AD treatment. Cox proportional
hazards model was used to estimate risk ratios of relapse with 95% confidence
intervals for each adherencemeasure. RESULTS:A total of 88,079 patients satisfied
the selection criteria, among which mean age of 45.2 years and 67.3% of women.
Overall relapse rate was 29.5%. Adherence (MPR75%) or persistence (duration of
uninterrupted therapy 90 days) showed non-significant estimates of relapse risk
(aRR0.99[0.97-1.02] and 1.01[0.97-1.04], respectively). Patients who switched AD
class within 180 days showed increased risk of relapse (aRR1.18[1.15-1.21]).
CONCLUSIONS: Various definitions of adherence led to different estimates of re-
lapse rate. Diverse aspects of adherence should be considered when studying the
association between the medication adherence and clinical outcomes.
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OBJECTIVES: The Patient Health Questionnaire-4 (PHQ-4; Kroenke, 2009) is a com-
posite instrument constructed from the GAD-2 and PHQ-2 questionnaire assess-
ments of depression and anxiety symptoms.We sought to build on prior validation
of the instrument by evaluating the reproducibility of the PHQ-4 and testing equiv-
alence between paper and electronic administrationmodes.METHODS:The PHQ-4
and other questionnaire measures were administered to a sample of adults re-
cruited through newspaper and web-based advertisements in eight US cities. Par-
ticipants were randomized to complete the PHQ-4 on either paper or computerized
format. A one-week retest was completed at home. Reproducibility and mode
equivalence were assessed using the intraclass correlation coefficient (ICC). Cron-
bach’s alpha was calculated to assess internal consistency. To assess convergent
validity, the correlation of the PHQ-4 to theMental Component Subscore (MCS) and
the Mental Health Index (MHI-5) of the SF-36 was calculated. T-tests were used to
assess the difference in PHQ scores by participants’ self-reported prior diagnosis of
clinical depression. RESULTS: Of the 258 participants that completed baseline as-
sessment, 251 (97%) completed the one-week retest. The mean age of participants
was 48.6 years, 61% were female, and 71% were Caucasian. About half (n130;
50.4%) reported a prior depression diagnosis. The mean PHQ-4 score was 4.0(3.3),
and the ICC between paper and computerized administration was 0.86. The ICC for
the one-week retest was 0.88, and the PHQ-4 was found to be internally consistent
(Cronbach’s alpha0.90). Significant correlations were found with the MCS
(r0.79; p0.001) and the MHI-5 (r0.86; p0.001), and the instrument discrim-
inated between participants with and without prior depression diagnoses (mean
PHQ-4 scores of 5.8 vs. 2.1, p0.001). CONCLUSIONS: The PHQ-4 was observed to
have adequate reproducibility and internal consistency; appropriate convergent
validity; and significantly discriminates between participants with prior diagnoses
of depression. Equivalence between paper and web-based administration was
demonstrated.
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OBJECTIVES: Sample size determination is critical in planning psychometric stud-
ies in order to achieve stable results. Confirmatory factor analysis (CFA) is an es-
sential aspect of content validation and for psychometric studies. The current
study reviewed three approaches for CFA-based power analyses: N:q rule-of-
thumb (N:q), RMSEA-based sample size (RMSEA-BSS), and Monte Carlo simulation
(MC). METHODS: N:q states 10 (reliable loadings) or 20 participants (less reliable
loadings) are required for every free parameter. RMSEA-BSS uses the sampling
distribution of RMSEA to determine the power of a CFA for a predicted level of
RMSEAversus a given RMSEA criterion (similar to the power of a t-test for onemean
versus another). the MC is used to investigate the performance of statistical esti-
mators under various conditions wherein data are generated for over k10,000
simulated datasets to understand the sampling distributions of various parame-
ters. MC has many benefits, including statistical estimates of the sample size re-
quirements for a very specific CFAmodel. These three approaches were examined
on the CFA for a common 10-itemdepression instrument. RESULTS: For n:Q, a total
of 22 free parameters were present, thereby requiring between 220 or 440 subjects.
RMSEA-BSS was calculated using a free website (people.ku.edu/preacher/rmsea/
rmsea.htm), resulting in a sample size estimate of 283 (alpha0.05, CFA df31,
power0.8, RMSEA criterion0.06, andRMSEAestimate0.02). A sample size of 183
was calculated using MC. CONCLUSIONS:N:q is simple yet the least accurate tech-
nique used. The RMSEA-BSS approach is not as accurate nor as flexible as MC, nor
as quick as N:q. It is accessible to most psychometricians, however, and often
provides sufficient accuracy. The MC is sophisticated and highly accurate; it can
include almost any latent modeling variant, thereby allowing for excellent speci-
ficity, its only downside is its complexity. The current CFA inMCprovided amarked
savings in sample size.
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DEATH IN DUAL ELIGIBLE ELDERLY NURSING HOME RESIDENTS USING
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OBJECTIVES: To evaluate the performance of two instrument variables, namely
physician and nursing home facility preference, to examine the risk of death in
dual eligible elderly nursing home residents using antipsychotic agents.
METHODS: A retrospective cohort design involving dual eligible nursing home
residents 65 years and above was used. An instrumental variable analysis was
conducted to evaluate the risk of mortality within 180 days of antipsychotic expo-
sure. The physician’s preference was operationalized based on the most recent
antipsychotic prescription initiated by the physician. Nursing home facility pref-
erence was defined as the most frequently initiated antipsychotic agent in the
nursing home. The performance of each instruments was evaluated based on the
strength of association, covariate balance, and explanatory power in addition to
endogeneity tests. The risk of deathwasmodeled using extended Cox Proportional
Hazardmodel based on two-stage residual inclusionmethod for instrumental vari-
able analysis. RESULTS: Physician preference [Odd Ratio (OR) 3.97] and nursing
home facility preference (OR 4.54) were strongly associatedwith antipsychotic use.
The explanatory power in the multivariate models and covariate balance in the
preference groupswere similar with both instruments. Instrumental variable anal-
ysis involving physician preference, however, did not meet the criteria for endoge-
neity (Wu-Hausman F  1.49, P  0.22). Using nursing home facility preference as
an instrument, the extended Cox model revealed that risk of death is greater
among typical antipsychotic users in the initial 40 days [Hazard Ratio (HR) 2.76, 95%
CI 2.11-3.62] but decreases after 40 days [HR 1.44, 95% CI 1.10-1.88] when compared
to atypical users. CONCLUSIONS: Nursing home facility preference appears to be
valid instrument in the nursing home population. Evaluation of instruments is
critical in implementing instrumental variable analysis for pharmacoepidemiology
research.
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OBJECTIVES: Registries are increasingly used to collect information on effective-
ness of new medications in real-world practice settings. Conducting a registry
study focused on providers who treat vulnerable populations and have limited
research experience can present unique challenges. The Research and Evaluation
of Antipsychotic Treatment in Community Behavioral Health Organizations OUT-
comes (REACHOUT) Registry is a naturalistic, longitudinal study of patients receiv-
ing primary treatment at community behavioral health organizations (CBHOs) to
provide information on paliperidone palmitate, risperidone long-acting therapy,
and other antipsychotics. This presentation discusses lessons learned thus far
from the REACH OUT study.METHODS: REACH OUT recruits patients with schizo-
phrenia or bipolar type I disorder from multiple CBHOs in the United States. Pa-
tients are identified by treating clinicians and screened by research coordinators to
determine eligibility. A Web-based data collection tool is used to enter data ob-
tained from patient self-reports, interviewer/clinician assessments, and medical
records abstraction. Patients will be followed for 1 year with assessments at base-
line, 6 months, and 12 months. RESULTS: Lessons learned thus far are 1) the value
of collaborating with the providermember organization to recruit sites; 2) the need
for buy-in from site management; 3) the importance of identifying dedicated staff
committed to research endeavors; 4) the importance of selection of instruments
that balance data collection burden and the desire for a variety of outcome mea-
sures; 5) benefits of vetting the draft protocol with potential sites to assess feasi-
bility; and 6) the importance of working with sites to address individual needs (e.g.,
local internal review board approval). CONCLUSIONS: Registry studies focusing on
patients treated by safety net providers, often with limited research experience,
require unique considerations. Working closely with sites up-front and obtaining
buy-in from site management and research staff have been crucial to REACH OUT
thus far.
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PATIENTS WITH ALZHEIMER’S DISEASE
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OBJECTIVES: Co-prescription of anticholinergic drugs with the traditional cholin-
esterase inhibitors treatment in patients suffering fromAlzheimer’s disease (AD) is
not recommended. Yet the extent of anticholinergic drugs use is unknown. Con-
versely, the prescription of anticholinergic drugs is not contraindicated with the
N-Methyl-D-Aspartic acid (NMDA) receptor antagonist. This study evaluates the
pattern of usage of drugs with anticholinergic activity in geriatric patients with AD
receiving cholinesterase inhibitors and NMDA receptor antagonist.METHODS: 654
patients suffering from AD above the age of 65 years were analyzed from NNHS
2004. The co-prescribed anticholinergic drugs were given a score of 0 to 3 using the
Clinician-Rated Anticholinergic Drug Scale with values ranging from no, mild,
A201V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
moderate and high anticholinergic activity respectively. Frequency of the use of
drugs having anticholinergic activity prescribed along with cholinesterase inhibi-
tors and NMDA receptor antagonist was compared using the Chi square test.
RESULTS: Of the patients with AD, 654 patients were given cholinesterase inhibi-
tors and NMDA receptor antagonist. Most of the AD patients were prescribed with
cholinesterase inhibitors (86.69%) as compared to NMDA receptor antagonist
(14.83%). 98.94% of patients on cholinesterase inhibitors and 93.82% on NMDA
receptor antagonist were co-prescribed drugswith anticholinergic properties. Sim-
ilar percent of patients on cholinesterase inhibitors andNMDA receptor antagonist
were co-prescribed drugswithmild (65.43%vs 63.92%, p0.7723),moderate (22.40%
vs 21.65%, p0.8699) and high (11.11% vs 8.25%, p0.3990) anticholinergic activity.
No statistical difference in prescribing moderate to high anticholinergic agents for
treating Depression, Convulsions and Parkinson’s disease was found in AD pa-
tients being treated with cholinesterase inhibitors and NMDA receptor antagonist.
CONCLUSIONS: Patients with AD receiving cholinesterase inhibitors or NMDA re-
ceptor antagonist appear to be co-prescribed drugs havingmoderate and high level
of anticholinergic activity without any distinction. Physicians should be more pru-
dent in co-prescribing drugs with anticholinergic activity in patients with AD due
to the high risk of adverse reactions.
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OBJECTIVES: To study the prevalence of comorbid conditions in a population of
patients with Multiple Sclerosis (MS).METHODS: In a retrospective analysis, inte-
grated medical and pharmacy claims data (IMS LifeLink™ Health Plan Claims and
Longitudinal Prescriptions databases) were analyzed to select patients with an active
diagnosis of MS (ICD-9 code 340.*) during the 2009 calendar year. The presence of
comorbidities was also determined using ICD-9 codes present on medical claims.
Prescription drug use was evaluated by pharmacy claims and drug-specific billing
codes.RESULTS: From the database, 18,013 patientswithMSwere identified. About
two-thirds (67.6%) of patients were between 18 and 55 years of age, and 77.6%were
female. Evidence of specific chronic conditions was substantial and included: hy-
perlipidemia (seen in 36.1% of patients), HTN (32.9%), diabetes (10.8%), asthma
(8.3%), cardiac arrhythmias (7.2%), COPD (4.5%), and CHF (1.6%). The presence of
any respiratory conditions (asthma or COPD) was present in 11.4% of patients,
cardiovascular conditions (HTN, CHF, arrhythmias) in 37.3%, and metabolic condi-
tions (DM, HTN, hyperlipidemia) in 50.5%. Though the prevalence of many condi-
tions was age and gender dependent, their prevalence was independent of treat-
ments including disease-modifying treatments (DMTs) such as interferon,
glatiramer acetate, and natalizumab. CONCLUSIONS: This analysis illustrates the
complexity of the case-mix of patients with MS. An increasing amount of evidence
suggests that physical and mental comorbidities, and adverse health factors are
common and can affect the disease. Because of the high prevalence of comorbidi-
ties, any treatment decisions should be carefully considered and should be indi-
vidualized in order to optimize outcomes and reduce the potential interactions
between treatment and comorbidities.
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OBJECTIVES:Comorbidities in individualswithMSadd to the complexity of disease
management. A better understanding of the nature and prevalence of comorbid
illness in MSmay improve patient outcomes. The objective of this research was to
gain a better understanding of the comorbid illnesses present in individuals with
MS compared to individualswithoutMS.METHODS:TheNational Health andWell-
ness Survey (NHWS) is an Internet-based annual study of the healthcare attitudes
and behaviors of a US representative adult sample. Demographics and comorbidi-
ties were compared between individuals with diagnosed MS and individuals with-
out MS. RESULTS: Compared to subjects without MS, a greater proportion of sub-
jects with MS reported being female (64.3% vs. 51.3%; p0.001) and being white
(non-hispanic) (78.7% vs. 74.0%; p0.006). Subjects with MS reported more comor-
bidity compared to subjects without MS (Charlson Comorbidity Index: 0.97 vs. 0.82;
p0.001). Neurologic symptoms and conditions (pain 56.7% vs. 37.8%, headache
55.8% vs. 44.6%,migraine 29.5% vs. 16.4%, restless leg syndrome 18.7% vs. 7.8%, and
stroke 5.2% vs. 1.4%; p0.001), and psychiatric symptoms and conditions (sleep
difficulties 43.3% vs. 29.6%, depression 39.7% vs. 23.5%, anxiety 33.0% vs. 22.6%,
insomnia 28.5% vs. 17.8%, and panic disorder 8.2% vs. 3.6%; p0.001) were more
common in subjects with MS compared to those without MS. Rates for hyperten-
sion (33.6% vs. 32.8%; p0.968) and high cholesterol (32.3% vs. 30.9%; p0.669) were
similar but cardiovascular conditions such as angina (4.8% vs. 2.9%; p0.001), ar-
rhythmia (4.8% vs. 2.7%; p0.003), and peripheral arterial disease (3.7% vs. 1.4%;
p0.001) were higher for MS subjects. CONCLUSIONS: As expected, individuals
with MS have significant comorbid illness compared to individuals without MS.
Neurologic and psychiatric conditions and symptoms are common and typically
more prevalent inMS. Cardiovascular risk factors are similar to individualswithout
MS but higher rates of cardiovascular conditions were observed.
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OBJECTIVES: To understand how shift work disorder (SWD) affected the lives of
shift workers (SWs) and how SWD was diagnosed from the perspective of health
care professionals (HCPs) and SWs.METHODS: Two separate online surveys were
administered to: (1) SWs with/out SWD and (2) HCPs. Participation in the SWs
survey required 21 hours per week working shifts in the previous 2 weeks, a
diagnosis of SWD or10 score on the Epworth Sleepiness Scale (ESS), and5 score
on any of the subscales of the Sheehan Disability Scale (SDS). Participation in the
HCP survey required3 years in pre-designated specialties and at least 75% of their
time spent in patient care. RESULTS: A total of 260 respondents complete the SWs
survey and 673 the HCP survey. SWnegatively impacted respondents’ energy level,
social life, and emotional and physical health. SWs also reported a loss of concen-
tration (87%), mistakes (69%), and an injury (11%) at work. Many respondents used
caffeine and 57% of diagnosed respondents received prescription medication to
treat SWD symptoms. Of those SWs without diagnosed SWD, 23% denied having
excessive sleepiness despite scoring10 on the ESS and having functional impair-
ment (SDS). For those SWs who consulted with their HCPs, SWs initiated this con-
versation more than HCPs (82% vs. 13%). HCPs believe that 67% of total SWD is
never suspected by physicians and that 50% of SWD is undiagnosed because SWD
is oftenmasked by other conditions and/ormisdiagnosed.CONCLUSIONS:Respon-
dents reported that excessive sleepiness and insomnia associated with SW seri-
ously impacted their lives at home and at work. SWs do not always recognize their
SWD symptoms and are more likely to initiate a discussion of those symptoms
than HCPs. HCPs believe that SWD is often missed as it is masked by other comor-
bidities or misdiagnosed.
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OBJECTIVES: To assess Parkinson’s Disease (PD) progression using the Hoehn and
Yahr (H&Y) scale over the complete disease course based on systematic literature
reviewwithmeta-analysis. No systematic review of PD studies usingH&Yhas been
undertaken. Such findings could support models to evaluate economic effects of
disease modifying therapies. METHODS: A systematic literature review (PubMed)
was conducted to identify research since 1990 that reported longitudinal H&Y out-
comes to obtain progression time data. Reference lists from retrieved articles were
also reviewed and supplemented with recommendations from an expert neurolo-
gist. Statistical moments (e.g., survival at time t, median time to progress) were
extracted and expected time to progress to the subsequent stage was calculated
assuming a constant hazard rate of progression with a binomial distribution for
progression rates. Average time to progress through all stages of disease was cal-
culated. Random effects meta-analysis was performed to assess heterogeneity be-
tween studies between each stage in progression. RESULTS: Of 554 identified rel-
evant titles, 56 articles were reviewed. Ten studies, including one open label
extension (OLE) trial and nine cohort studies, reported longitudinal H&Y outcomes
for 3,687 patients observed over an average of 13.5 years.Weighted by study sample
sizes, expected time to progress from H&Y 1 to H&Y 5 was 162.1 months. The OLE
trial had longest expected total progression time (431.8 months, N110); other
studies ranged from 102.0 to 171.7 months. Time from H&Y stage 1–stage 2, 2–3,
3–4, and 4–5 were 32.3, 60.5, 42.9 and 26.4 months, respectively. Meta-analysis
indicated significant heterogeneity in progression time between studies (I295%).
Omitting single studies did not affect pooled estimates. CONCLUSIONS: Economic
assessment of impacts of PD disease modification can consider expected progres-
sion rates over the full course of the disease. Progression rates are most rapid from
H&Y stage 4 to 5.
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OBJECTIVES: Relapse reduction is important for multiple sclerosis (MS) because
relapses lead to faster deterioration of patient health status. This study aims to
evaluate the impact of specialty care programs which mainly focus on mail-order,
professional monitoring and assessment for MS patients nationwide, compared to
usual care. METHODS: Administrative claims for people with MS were extracted
from the databases from a pharmacy management company for this retrospective
cohort study. Enrollees with continuous pharmacy benefit eligibility were followed
for three years. Patients exposed to specialty care programs were classified as
specialty care group. Relapses were considered to have occurred when patients
used steroids or were hospitalized due to MS. The outcomemeasures included the
risk, number of relapses, and time to relapse. Logistic, negative binomial, and
Cox-proportional hazards regressions were performed to compare between
groups. RESULTS: Study cohort consisted of 1731 eligible MS patients, of which
1427 received the specialty care. During the study period, 1634 relapses were iden-
tified with amean annual relapse rate of 0.3 among specialty care group versus 0.4
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